Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

NCT04869982 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

6138

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: RZV
DRUG: Placebo

Sponsor

GlaxoSmithKline